Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Biology and Signal Transduction

1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling

Ping-Tsung Chen, Ching-Chuan Hsieh, Chun-Te Wu, Tzu-Chen Yen, Paul-Yang Lin, Wen-Cheng Chen and Miao-Fen Chen
Ping-Tsung Chen
1Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
2Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching-Chuan Hsieh
1Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
3General Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chun-Te Wu
4College of Medicine, Chang Gung University, Taoyuan, Taiwan.
5Department of Urology, Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tzu-Chen Yen
6Nuclear Medicine Department, Chang Gung Memorial Hospital at Linkou, Linkou, Taiwan.
7Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital at Linkou, Linkou, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul-Yang Lin
8Department of Pathology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen-Cheng Chen
4College of Medicine, Chang Gung University, Taoyuan, Taiwan.
9Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miao-Fen Chen
4College of Medicine, Chang Gung University, Taoyuan, Taiwan.
9Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: miaofen@adm.cgmh.org.tw
DOI: 10.1158/1535-7163.MCT-14-0952 Published June 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Effects of calcitriol on tumor growth in vitro and in vivo. A, effect of calcitriol on the proliferation of CE81T and TE2 cancer cells in vitro as determined by viable cell counting. The y-axis represents the viable cell number. Data represent the means ± SEM. *, P < 0.05. B, effect of calcitriol treatment on ectopic tumor growth. Data represent the means ± SD of three independent experiments (9 animals per treated group in total). *, P < 0.05. Representative slides using Ki-67 nuclear staining in tumors 21 days after implantation was also shown with magnification ×400. C, effect of calcitriol treatment on cell death, as assessed by FACS with Annexin V–PI staining using cells under control condition or treated with calcitriol for 72 hours. The results of representative slides are shown. D, the changes of apoptosis and cell-cycle–associated proteins in vitro were evaluated by immunoblotting. E, immunoblotting analysis of VDR, p21, Bax, and Bcl-2 expressions using proteins extracted from tumor samples 21 days after implantation.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Effects of calcitriol on aggressive tumor behavior and EMT changes. A, effect of calcitriol on the invasiveness of esophageal cancer cells in vitro. Representative slides and quantitative data (y-axis shows the relative ratio, normalized to the number of invading cells under control conditions) are shown. *, P < 0.05. B, effect of calcitriol treatment on the invasive capacities was evaluated by murine orthotopic tumor implantation. The results are shown by representative slides and quantitative data. The y-axis represents the relative ratio of esophageal tumor invading into adjacent structure 2 weeks after implantation. *, P < 0.05 (white circle, excision location; black arrow, esophagus; red arrow, tumor). C, the changes of E-cadherin expression were evaluated by immunofluorescence in vitro, and the results of representative slides are shown. Scale bars, 25 μm. D, effect of calcitriol treatment on EMT-associated proteins. The changes in the levels of EMT-associated proteins were evaluated by immunoblotting in vitro. E, levels of VEGF and MMP-9 expression evaluated using immunohistochemical analysis in tumors 21 days after implantation. The results of representative slides are shown with magnification ×400.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Effects of calcitriol on IL6/STAT3 signaling in esophageal SCC. A, effect of calcitriol treatment on the expression of IL6 and activated STAT3 were evaluated by immunoblotting in vitro. B, the levels of IL6 in cellular supernatants were examined by ELISA in vitro. Columns represent the means ± SEM. *, P < 0.05. C, levels of IL6 and p-STAT3 evaluated using immunohistochemistry and immunoblotting analysis in ectopic tumors 21 days after implantation. The results of representative slides are shown with magnification ×400. Calcitriol treatment significantly decreased the expression of IL6. D, effect of calcitriol treatment on the expression of phosphorylated p38 was evaluated by immunoblotting. E, the expression levels of IL6 and p-STAT3 were evaluated by immunofluorescence using CE81T cells incubated in the presence of indicated dosage of calcitriol or p38 inhibitor for 48 hours and the results of representative slides are shown. Scale bars, 50 μm. F, effect of p38 MAPK inhibitor on the expression of IL6 and p-STAT3 was evaluated by immunoblotting.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Evaluation of esophageal tumor formation using histologic examination and animal micro-PET imaging and its relationship with IL6 levels and MDSC recruitment. A, images of the gross lesions and pathologic findings of tissue sections from animals treated with 4-NQO or vehicle for 16 weeks and then followed for 12 to 14 weeks. The representative slides are shown with magnification ×100 and ×400. B, representative PET images from mice treated with 4-NQO and diagnosed with invasive carcinoma, compared with benign lesions (hyperplasia/papilloma). The tumor-to-muscle SUVR was calculated from the micro-PET scans. Data points represent the means ± SEMs. C, flow cytometric analysis of CD11b+Gr1+ cells from mice exhibiting hyperplasia/papilloma or invasive carcinoma after histologic analysis. Representative images and quantitation are shown. Columns represent the means ± SEM. *, P < 0.05. D, IL6 levels in mice were measured using ELISA and quantitative data are shown. Columns represent the means ± SEM. *, P < 0.05.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Effect of calcitriol on tumor progression related to IL6 signaling in vivo. A, quantitative data of SUVR of esophageal lesion in 4-NQO–treated mice with or without calcitriol treatment or regulation of IL6. The tumor-to-muscle SUVR was calculated from the micro-PET scans. Columns represent the means ± SEM. B, representative images of gross lesions and the pathologic findings on sectioned tissue samples from 4-NQO mice with or without calcitriol or regulation of IL6. Quantitative data assessing the incidence of invasive esophageal tumors are shown. Columns represent the means ± SEM. *, P < 0.05. C, flow cytometric analysis of CD11b+Gr1+ cells from 4-NQO–treated mice with or without calcitriol or regulation of IL6. Representative images and quantitative data are shown. Columns represent the means ± SEM. D, effect of calcitriol treatment on the expression of IL6 in esophageal specimen from mice (control, C57 mice with vehicle only; 4NQO, 4-NQO–treated mice; 4-NQO + calcitriol, 4-NQO–treated mice with calcitriol injection; 4-NQO + IL6 KO, 4-NQO–treated IL6 KO mice) were evaluated by immunofluorescence and real-time RT-PCR. *, P < 0.05.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Effect of calcitriol treatments on the function and recruitment of MDSC in vivo. A, effect of calcitriol on MDSC recruitment in vivo (control, C57 mice without treatment; 4NQO, 4-NQO–treated mice; IL6, IL6-stimulated mice; IL6 + calcitriol, IL6-stimulated mice with calcitriol injection) were evaluated by FACS. B, immunofluorescence staining revealed that calcitriol attenuated the IL6-induced increase in the levels of activated STAT3 and ROS in MDSC from murine spleen. (top row, low power field with scale bars, 50 μm; bottom row, high power field with scale bars, 25 μm). Representative images and quantitative data are shown. C, the suppressing ability of MDSC for T-cell proliferation was evaluated by FACS. Representative images and quantitative data are shown (stimulation alone, CD8+ T cells with anti-CD3/CD28 stimulation beads without CD11b+ cells; +CD11b cells, T cells with stimulation and coculture with CD11b+ cells from control mice, or IL6-stimulated mice with or without calcitriol injection). *, P < 0.05.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary methods and legends - Supplementary methods and legends for supplementary Figures
    • Supplementary Figure 1 - Supplementary Figure 1. Effects of Calcitriol on tumor cell proliferation in vitro
    • Supplementary Figure 2 - Supplementary Figure 2. Effects of Calcitriol on migration capacity and EMT in vitro
    • Supplementary Figure 3 - Supplementary Figure 3. Effects of blocking IL-6 on tumor growth and EMT in vitro
    • Supplementary Figure 4 - Supplementary Figure 4. Effects of Calcitriol on IL-6/STAT3 signaling in esophageal SCC
    • Supplementary Figure 5 - Supplementary Figure 5. IL-6 levels in 4-NQO-treated mice with or without Calcitriol or IL-6 injection were measured using ELISA
    • Supplementary Figure 6 - Supplementary Figure 6. Effect of Calcitriol treatments on the function and recruitment of MDSC in vivo.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 14 (6)
June 2015
Volume 14, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Ping-Tsung Chen, Ching-Chuan Hsieh, Chun-Te Wu, Tzu-Chen Yen, Paul-Yang Lin, Wen-Cheng Chen and Miao-Fen Chen
Mol Cancer Ther June 1 2015 (14) (6) 1365-1375; DOI: 10.1158/1535-7163.MCT-14-0952

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Ping-Tsung Chen, Ching-Chuan Hsieh, Chun-Te Wu, Tzu-Chen Yen, Paul-Yang Lin, Wen-Cheng Chen and Miao-Fen Chen
Mol Cancer Ther June 1 2015 (14) (6) 1365-1375; DOI: 10.1158/1535-7163.MCT-14-0952
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Ormeloxifene and Prostate Cancer
  • Proinflammatory Cytokines and Drug Resistance
  • Decitabine and the MUC1-C Inhibitor Synergize in CTCL
Show more Cancer Biology and Signal Transduction
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement